All-oral, DAA options for HCV effective & well tolerated in patients with decompensated cirrhosis

(European Association for the Study of the Liver) Interim data presented today at The International Liver CongressTM 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C is well tolerated and highly effective in patients with decompensated cirrhosis. Sustained virologic response at four weeks was shown to be: sofosbuvir/ribavirin: 75 percent; sofosbuvir/simeprevir: 77 percent; sofosbuvir/simeprevir/ribavirin: 81 percent.
Source: EurekAlert! - Biology - Category: Biology Source Type: news

Related Links:

Authors: Schauer C, Mules T, Rijnsoever MV, Gane E Abstract BACKGROUND: Regular surveillance for hepatocellular carcinoma (HCC) in patients with chronic hepatitis B viral (HBV) infection and hepatitis C (HCV) cirrhosis improves survival by earlier detection of the cancer at an earlier stage when curative intervention may still be possible. We compared patient characteristics, surveillance history and outcomes in patients presenting with advanced HCC secondary to HBV and HCV. METHOD: In this retrospective study, clinical databases and notes were reviewed in all cases of advanced HCC related to HBV or HCV referre...
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
ConclusionIn this large real-life single-center HCV cohort from China, oral DAAs were highly effective and well-tolerated. Further and larger-scale studies are needed to evaluate their clinical safety and efficacy.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusion and Relevance: Based on these findings, a recommendation for extension of therapy cannot be made for patients with detectable HCV RNA at week 4 of treatment at this time. Cost analyses may help guide recommendations to re-treat rare failures versus extend therapy in all slow responders. PMID: 32406244 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Tags: Ann Pharmacother Source Type: research
Abstract Background/Aims: Chronic hepatitis C (CHC) treatment has dramatically improved since direct-acting antiviral (DAA) therapy was introduced. However, the use of DAA therapy in CHC patients with hepatocellular carcinoma (HCC) remains controversial. We investigated the DAA treatment response in CHC patients with HCC. Methods: We retrospectively analyzed CHC patients treated with DAA from 2016 to 2018. Patients were divided into two groups based on their HCC-history before DAA therapy. Baseline characteristics, sustained virologic response at 12 weeks (SVR 12), and HCC recurrence after DAA therapy were ev...
Source: The Korean Journal of Internal Medicine - Category: Internal Medicine Authors: Tags: Korean J Intern Med Source Type: research
A juggernaut of innate &adaptive immune cells in chronic hepatitis C. Indian J Med Res. 2020 Apr;151(4):279-286 Authors: Tomer S, Arora SK Abstract Hepatitis C virus (HCV) is a small positive-sense, single-stranded RNA virus, the causal organism for chronic hepatitis. Chronic hepatitis leads to inflammation of liver, causing cirrhosis, fibrosis and steatosis, which may ultimately lead to liver cancer in a few cases. Innate and adaptive immune responses play an important role in the pathogenesis of HCV infection, thus acting as an important component in deciding the fate of the disease. Numerous st...
Source: The Indian Journal of Medical Research - Category: Biomedical Science Authors: Tags: Indian J Med Res Source Type: research
We report a case of hepatic hydrothorax in a 55-year-old female patient with HCV cirrhosis, which exhibited a spontaneous decrease in pleural effusion after direct antiviral agent (DAA) therapy. In cases of HCV cirrhosis, DAAs are worth administering before treatment by TIPS or liver transplantation. PMID: 32098464 [PubMed - in process]
Source: Korean J Gastroenter... - Category: Gastroenterology Authors: Tags: Korean J Gastroenterol Source Type: research
ConclusionsThe efficacy and safety profiles observed in this study support the administration of nivolumab in mRCC patients infected with HCV and warrant further investigation.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Objectives Hepatocellular carcinoma can develop after hepatitis C virus eradication. We developed a new hepatocellular carcinoma risk score (HCC-SVR score) based on independent predictors for chronic hepatitis C after sustained virological response. Methods Between 2003 and 2016, a total of 1193 patients with chronic hepatitis C who achieved sustained virological response through antiviral therapy were included (669 for training cohort and 524 for validation cohort). The HCC-SVR score was developed using multivariate Cox proportional hazards regression modelling. Results Hepatocellular carcinoma (n = 19) occurred m...
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
Hepatitis C virus (HCV) is a major cause of liver disease including metabolic disease, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). HCV induces and promotes liver disease progression by perturbing a range of survival, proliferative, and metabolic pathways within the proinflammatory cellular microenvironment. The recent breakthrough in antiviral therapy using direct-acting antivirals (DAAs) can cure>90% of HCV patients. However, viral cure cannot fully eliminate the HCC risk, especially in patients with advanced liver disease or comorbidities. HCV induces an epigenetic viral footprint that promotes a pro-onco...
Source: Cold Spring Harbor perspectives in medicine - Category: Research Authors: Tags: Hepatitis C Viruses: The Story of a Scientific and Therapeutic Revolution PERSPECTIVES Source Type: research
Publication date: Available online 17 December 2019Source: Antiviral ResearchAuthor(s): Hee Sun Kim, Youngsu You, Jae Gon Mun, Changdev G. Gadhe, Heejo Moon, Jae Seung Lee, Ae Nim Pae, Michinori Kohara, Gyochang Keum, Byeong Moon Kim, Sung Key JangAbstractApproximately 71 million people suffer from hepatitis C virus (HCV) infection worldwide. Persistent HCV infection causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma, resulting in approximately 400,000 deaths annually. Effective direct-acting antiviral agents (DAAs) have been developed and are currently used for HCV treatment tar...
Source: Antiviral Therapy - Category: Virology Source Type: research
More News: Antiviral Therapy | Biology | Cirrhosis | Hepatitis | Hepatitis C | Liver | Politics | Study | Urology & Nephrology | Virology